A meta-analysis comprising ten studies found that the MTHFR gene RS1801131 polymorphism did not significantly impact the outcome of methotrexate (MTX) treatment in patients with rheumatoid arthritis (RA). This evidence concerns the gene MTHFR and rheumatoid arthritis.